Cerus Corp. CERS
Medical/Dental Instruments · IPO 1997 · data as of November 13, 2026
Cerus Corp. (CERS) is a healthcare company listed in the US with a market value of about $401M. In the twelve months to September 30, 2026 it had revenue of $254M and net income of -$7M, a net margin of -2.9%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: a price to free cash flow of 811.5, 5-year revenue growth of 15% a year, a 5-year average ROIC of -14%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 96% below the current price.
About Cerus
Cerus is listed in the US and classified in medical/dental instruments, IPO year 1997. Revenue went from $36M in 2014 to $234M in 2025, growth of about 18.4% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 8% over three years (dilution for shareholders). It spends 29% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- Positive free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $254M | $234M | $201M | $187M | $188M | $160M | $114M | $94M | $76M | $51M | $39M |
| Net income | -$7M | -$16M | -$21M | -$37M | -$43M | -$54M | -$60M | -$71M | -$58M | -$61M | -$63M |
| Free cash flow | $494000 | $1M | $9M | -$48M | -$28M | -$35M | -$43M | -$74M | -$32M | -$53M | -$54M |
| EPS (diluted) | $-0.03 | $-0.08 | $-0.11 | $-0.21 | $-0.24 | $-0.32 | $-0.37 | $-0.51 | $-0.44 | $-0.56 | $-0.62 |
| Net margin | -2.9% | -6.7% | -10.4% | -20.1% | -22.7% | -34.1% | -52.4% | -76.0% | -75.7% | -118.0% | -160.2% |
| ROIC | — | -4.2% | -7.3% | -16.0% | -17.4% | -24.5% | -28.4% | -44.9% | -37.9% | -65.9% | -62.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 4 analysts is $5.12, 158% above the current price; targets range from $4.00 to $6.50; the consensus rating is “Strong buy”; expected EPS is $-0.02 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Cerus stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 96% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Cerus pay a dividend?
Not currently.
Is Cerus a good stock to buy?
We do not give buy or sell advice. Cerus scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.